Table 3. Grade ≥ 3 (CTCAE) TEAEs in > 1 patient.

		Onapristone Dose
Preferred Term	Overall (N = 52) n (%)	10 mg BID (N = 12 a) n (%)	20 mg BID (N = 12 a) n (%)	30 mg BID (N = 6) n (%)	40 mg BID (N = 10) n (%)	50 mg BID (N = 6) n (%)	100 mg QD (N = 6) n (%)
Any Grade ≥ 3 TEAE	30 (58)	8 (67)	7 (58)	3 (50)	6 (60)	3 (50)	3 (50)
GGT increase	13 (25)	5 (42)	2 (17)	2 (33)	3 (30)	1 (17)	0
Asthenia	4 (8)	0	2 (17)	0	1 (10)	0	1 (17)
ALP increase	4 (8)	1 (8)	1 (8)	0	2 (20)	0	0
AST increase	3 (6)	2 (17)	1 (8)	0	0	0	0
ALT increase	2 (4)	1 (8)	1 (8)	0	0	0	0
Bilirubin increase	2 (4)	1 (8)	0	0	1 (10)	0	0
Disease progression	2 (4)	0	1 (8)	0	1 (10)	0	0
Peripheral edema	2 (4)	1(8)	0	0	1 (10)	0	0
Pyrexia	2 (4)	0	2 (17)	0	0	0	0

a. 1 patient randomized to 20mg was treated at 10mg BID and is included in all data tables as being at the 10mg dose level